非小细胞肺癌免疫治疗最新临床进展
摘要
<正>肺癌是在全球范围内发病率和死亡率呈上升趋势,其中最常见的为非小细胞肺癌(non-small cell lung cancer,NSCLC),约占肺癌总数的80%-85%~([1])。吸烟、环境污染等是引起肺癌发生的主要因素。在我国,肺癌的发病率和死亡率居恶性肿瘤首位,由于疾病的隐匿性,据统计每年仅有25%患者可被诊断为早期疾病~([2]),大多数患者发现时已处于肿瘤晚期,失去手术机会,而传统治疗方法副作用
引文
[1]LIU X,CHO W C.Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer[J].Clin Transl Med,2017,6(1):7.
[2]张星星,王胜,任薇,等.2016年肺癌研究述要[J].临床肺科杂志,2018,23(4):751-755.
[3]RECK M,POPAT S,REINMUTH N,et al.Metastatic non-smallcell lung cancer(NSCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2014,25(S3):iii27-iii39.
[4]何圆,尤长宣.非小细胞肺癌免疫治疗进展[J].中国肺癌杂志,2014,17(3):277-281.
[5]BEATTY G L,GLADNEY W L.Immune escape mechanisms as a guide for cancer immunotherapy[J].Clin Cancer Res,2015,21(4):687-692.
[6]MONTEIRO I D,CALIFANO R,MOUNTZIOS G,et al.Immunotherapy with checkpoint inhibitors for lung cancer:novel agents,biomarkers and paradigms[J].Future Oncol,2016,12(4):551-564.
[7]VANSTEENKISTE J,ZIELINSKI M,LINDER A,et al.Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer:phaseⅡrandomized study results[J].J Clin Oncol,2013,31(19):2396-2403.
[8]PUJOL J L,VANSTEENKISTE J F,DE PAS T M,et al.Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stageⅠBtoⅢMAGE-A3-Positive non-small-cell lung cancer[J].J Thorac Oncol,2015,10(10):1458-1467.
[9]RODRIGUEZ P C,POPA X,MARTINEZ O,et al.A phaseⅢclinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small-cell lung cancer patients[J].Clin Cancer Res,2016,22(15):3782-3790.
[10]NENINGER E,VERDECIA B G,CROMBET T,et al.Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer[J].J Immunother,2009,32(1):92-99.
[11]AERTS J G,HEGMANS J P.Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer[J].Cancer Res,2013,73(8):2381-2388.
[12]YOON S H.Immunotherapy for non-small cell lung cancer[J].Tuberc Respir Dis(Seoul),2014,77(3):111-115.
[13]BUTTS C,MURRAY N,MAKSYMIUK A,et al.Randomized phaseⅡB trial of BLP25 liposome vaccine in stageⅢB andⅣnonsmall-cell lung cancer[J].J Clin Oncol,2005,23(27):6674-6681.
[14]BUTTS C,SOCINSKI M A,MITCHELL P L,et al.Tecemotide(L-BLP25)versus placebo after chemoradiotherapy for stageⅢnonsmall-cell lung cancer(START):a randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(1):59-68.
[15]MITCHELL P,THATCHER N,SOCINSKI M A,et al.Tecemotide in unresectable stageⅢnon-small cell lung cancer in the phaseⅢSTART study:updated overall survival and biomarker analyses[J].Ann Oncol,2015,26(6):1134-1142.
[16]NEMUNAITIS J,JAHAN T,ROSS H,et al.Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX?vaccine in advanced-stage non-small-cell lung cancer[J].Cancer Gene Ther,2006,13(6):555-562.
[17]NEMUNAITIS J,DILLMAN R O,SCHWARZENBERGER P O,et al.PhaseⅡstudy of belagenpumatucel-L,a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer[J].J Clin Oncol,2006,24(29):4721-4730.
[18]GIACCONE G,BAZHENOVA L A,NEMUNAITIS J,et al.A phaseⅢstudy of belagenpumatucel-L,an allogeneic tumour cell vaccine,as maintenance therapy for non-small cell lung cancer[J].Eur J Cancer,2015,51(16):2321-2329.
[19]SKACHKOVA O V,KHRANOVSKA N M,GORBACH O I,et al.Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer[J].Exp Oncol,2013,35(2):109-113.
[20]LYNCH T J,BONDARENKO I,LUFT A,et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stageⅢB/Ⅳnon-small-cell lung cancer:results from a randomized,double-blind,multicenter phaseⅡstudy[J].J Clin Oncol,2012,30(17):2046-2054.
[21]RECK M,BONDARENKO I,LUFT A,et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer:results from a randomized,double-blind,multicenter phase 2 trial[J].Ann Oncol,2013,24(1):75-83.
[22]ISHIDA Y,AGATA Y,SHIBAHARA K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death[J].EMBO J,1992,11(11):3887-3895.
[23]VELCHETI V,SCHALPER K A,CARVAJAL D E,et al.Programmed death ligand-1 expression in non-small cell lung cancer[J].Lab Invest,2014,94(1):107-116.
[24]BRAHMER J,RECKAMP K L,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.
[25]GETTINGER S N,HORN L,GANDHI L,et al.Overall survival and long-term safety of nivolumab(anti-programmed death 1 antibody,BMS-936558,ONO-4538)in patients with previously treated advanced non-small-cell lung cancer[J].J Clin Oncol,2015,33(18):2004-2012.
[26]RIZVI N A,MAZI?RES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer(CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.
[27]KAZANDJIAN D,KHOZIN S,BLUMENTHAL G,et al.Benefitrisk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy:a report from the US food and drug administration[J].JAMA Oncol,2016,2(1):118-122.
[28]GARON E B,RIZVI N A,HUI R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372(21):2018-2028.
[29]RECK M,RODR?GUEZ-ABREU D,ROBINSON A G,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].N Engl J Med,2016,375(19):1823-1833.
[30]HERBST R S,BAAS P,KIM D W,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-smallcell lung cancer(KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.
[31]FEHRENBACHER L,SPIRA A,BALLINGER M,et al.Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer(POPLAR):a multicentre,open-label,phase 2 randomised controlled trial[J].Lancet,2016,387(10030):1837-1846.
[32]ANTONIA S,GOLDBERG S B,BALMANOUKIAN A,et al.Safety and antitumour activity of durvalumab plus tremelimumab in nonsmall cell lung cancer:a multicentre,phase 1b study[J].Lancet Oncol,2016,17(3):299-308.
[33]MORGAN R A,CHINNASAMY N,ABATE-DAGA D,et al.Cancer regression and neurological toxicity following anti-MAGE-A3 TCRgene therapy[J].J Immunother,2013,36(2):133-151.
[34]WEBER J S,YANG J C,ATKINS M B,et al.Toxicities of immunotherapy for the practitioner[J].J Clin Oncol,2015,33(18):2092-2099.
[35]CHAMPIAT S,DERCLE L,AMMARI S,et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1[J].Clin Cancer Res,2017,23(8):1920-1928.
[2]张星星,王胜,任薇,等.2016年肺癌研究述要[J].临床肺科杂志,2018,23(4):751-755.
[3]RECK M,POPAT S,REINMUTH N,et al.Metastatic non-smallcell lung cancer(NSCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2014,25(S3):iii27-iii39.
[4]何圆,尤长宣.非小细胞肺癌免疫治疗进展[J].中国肺癌杂志,2014,17(3):277-281.
[5]BEATTY G L,GLADNEY W L.Immune escape mechanisms as a guide for cancer immunotherapy[J].Clin Cancer Res,2015,21(4):687-692.
[6]MONTEIRO I D,CALIFANO R,MOUNTZIOS G,et al.Immunotherapy with checkpoint inhibitors for lung cancer:novel agents,biomarkers and paradigms[J].Future Oncol,2016,12(4):551-564.
[7]VANSTEENKISTE J,ZIELINSKI M,LINDER A,et al.Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer:phaseⅡrandomized study results[J].J Clin Oncol,2013,31(19):2396-2403.
[8]PUJOL J L,VANSTEENKISTE J F,DE PAS T M,et al.Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stageⅠBtoⅢMAGE-A3-Positive non-small-cell lung cancer[J].J Thorac Oncol,2015,10(10):1458-1467.
[9]RODRIGUEZ P C,POPA X,MARTINEZ O,et al.A phaseⅢclinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small-cell lung cancer patients[J].Clin Cancer Res,2016,22(15):3782-3790.
[10]NENINGER E,VERDECIA B G,CROMBET T,et al.Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer[J].J Immunother,2009,32(1):92-99.
[11]AERTS J G,HEGMANS J P.Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer[J].Cancer Res,2013,73(8):2381-2388.
[12]YOON S H.Immunotherapy for non-small cell lung cancer[J].Tuberc Respir Dis(Seoul),2014,77(3):111-115.
[13]BUTTS C,MURRAY N,MAKSYMIUK A,et al.Randomized phaseⅡB trial of BLP25 liposome vaccine in stageⅢB andⅣnonsmall-cell lung cancer[J].J Clin Oncol,2005,23(27):6674-6681.
[14]BUTTS C,SOCINSKI M A,MITCHELL P L,et al.Tecemotide(L-BLP25)versus placebo after chemoradiotherapy for stageⅢnonsmall-cell lung cancer(START):a randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(1):59-68.
[15]MITCHELL P,THATCHER N,SOCINSKI M A,et al.Tecemotide in unresectable stageⅢnon-small cell lung cancer in the phaseⅢSTART study:updated overall survival and biomarker analyses[J].Ann Oncol,2015,26(6):1134-1142.
[16]NEMUNAITIS J,JAHAN T,ROSS H,et al.Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX?vaccine in advanced-stage non-small-cell lung cancer[J].Cancer Gene Ther,2006,13(6):555-562.
[17]NEMUNAITIS J,DILLMAN R O,SCHWARZENBERGER P O,et al.PhaseⅡstudy of belagenpumatucel-L,a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer[J].J Clin Oncol,2006,24(29):4721-4730.
[18]GIACCONE G,BAZHENOVA L A,NEMUNAITIS J,et al.A phaseⅢstudy of belagenpumatucel-L,an allogeneic tumour cell vaccine,as maintenance therapy for non-small cell lung cancer[J].Eur J Cancer,2015,51(16):2321-2329.
[19]SKACHKOVA O V,KHRANOVSKA N M,GORBACH O I,et al.Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer[J].Exp Oncol,2013,35(2):109-113.
[20]LYNCH T J,BONDARENKO I,LUFT A,et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stageⅢB/Ⅳnon-small-cell lung cancer:results from a randomized,double-blind,multicenter phaseⅡstudy[J].J Clin Oncol,2012,30(17):2046-2054.
[21]RECK M,BONDARENKO I,LUFT A,et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer:results from a randomized,double-blind,multicenter phase 2 trial[J].Ann Oncol,2013,24(1):75-83.
[22]ISHIDA Y,AGATA Y,SHIBAHARA K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death[J].EMBO J,1992,11(11):3887-3895.
[23]VELCHETI V,SCHALPER K A,CARVAJAL D E,et al.Programmed death ligand-1 expression in non-small cell lung cancer[J].Lab Invest,2014,94(1):107-116.
[24]BRAHMER J,RECKAMP K L,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.
[25]GETTINGER S N,HORN L,GANDHI L,et al.Overall survival and long-term safety of nivolumab(anti-programmed death 1 antibody,BMS-936558,ONO-4538)in patients with previously treated advanced non-small-cell lung cancer[J].J Clin Oncol,2015,33(18):2004-2012.
[26]RIZVI N A,MAZI?RES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer(CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.
[27]KAZANDJIAN D,KHOZIN S,BLUMENTHAL G,et al.Benefitrisk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy:a report from the US food and drug administration[J].JAMA Oncol,2016,2(1):118-122.
[28]GARON E B,RIZVI N A,HUI R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372(21):2018-2028.
[29]RECK M,RODR?GUEZ-ABREU D,ROBINSON A G,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].N Engl J Med,2016,375(19):1823-1833.
[30]HERBST R S,BAAS P,KIM D W,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-smallcell lung cancer(KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.
[31]FEHRENBACHER L,SPIRA A,BALLINGER M,et al.Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer(POPLAR):a multicentre,open-label,phase 2 randomised controlled trial[J].Lancet,2016,387(10030):1837-1846.
[32]ANTONIA S,GOLDBERG S B,BALMANOUKIAN A,et al.Safety and antitumour activity of durvalumab plus tremelimumab in nonsmall cell lung cancer:a multicentre,phase 1b study[J].Lancet Oncol,2016,17(3):299-308.
[33]MORGAN R A,CHINNASAMY N,ABATE-DAGA D,et al.Cancer regression and neurological toxicity following anti-MAGE-A3 TCRgene therapy[J].J Immunother,2013,36(2):133-151.
[34]WEBER J S,YANG J C,ATKINS M B,et al.Toxicities of immunotherapy for the practitioner[J].J Clin Oncol,2015,33(18):2092-2099.
[35]CHAMPIAT S,DERCLE L,AMMARI S,et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1[J].Clin Cancer Res,2017,23(8):1920-1928.